NASDAQ:OPK OPKO Health - OPK Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding OPKO Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.35 -0.01 (-0.74%) (As of 03/20/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.28▼$1.3850-Day Range$1.06▼$1.6152-Week Range$1.00▼$3.75Volume4.37 million shsAverage Volume4.65 million shsMarket Capitalization$1.04 billionP/E RatioN/ADividend YieldN/APrice Target$3.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability OPKO Health MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside159.3% Upside$3.50 Price TargetShort InterestBearish9.01% of Float Sold ShortDividend StrengthN/ASustainability-1.65Upright™ Environmental ScoreNews Sentiment0.67Based on 7 Articles This WeekInsider TradingAcquiring Shares$6.18 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.29) to ($0.24) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.44 out of 5 starsMedical Sector172nd out of 988 stocksPharmaceutical Preparations Industry66th out of 482 stocks 3.5 Analyst's Opinion Consensus RatingOPKO Health has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.50, OPKO Health has a forecasted upside of 159.3% from its current price of $1.35.Amount of Analyst CoverageOPKO Health has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted9.01% of the float of OPKO Health has been sold short.Short Interest Ratio / Days to CoverOPKO Health has a short interest ratio ("days to cover") of 13.1, which indicates bearish sentiment.Change versus previous monthShort interest in OPKO Health has recently increased by 7.70%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldOPKO Health does not currently pay a dividend.Dividend GrowthOPKO Health does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreOPKO Health has received a 66.30% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Calcifediol", "Diagnostic test kits", and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for OPKO Health is -1.65. Previous Next 3.7 News and Social Media Coverage News SentimentOPKO Health has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.35 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for OPKO Health this week, compared to 3 articles on an average week.Social Mentions This WeekMarketBeat has tracked 1 reddit mention for OPKO Health this week, compared to 0 mentions on an average week.Search Interest92 people have searched for OPK on MarketBeat in the last 30 days. This is an increase of 46% compared to the previous 30 days.MarketBeat Follows16 people have added OPKO Health to their MarketBeat watchlist in the last 30 days. This is an increase of 220% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, OPKO Health insiders have bought more of their company's stock than they have sold. Specifically, they have bought $6,180,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders40.97% of the stock of OPKO Health is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 23.49% of the stock of OPKO Health is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for OPKO Health are expected to grow in the coming year, from ($0.29) to ($0.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OPKO Health is -3.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OPKO Health is -3.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOPKO Health has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About OPKO Health (NASDAQ:OPK) StockOPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment includes the clinical laboratory operations of BioReference, as well as point-of-care operations. The Pharmaceuticals segment includes pharmaceutical operations in Chile, Mexico, Ireland, Israel, and Spain and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.Read More Receive OPK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OPKO Health and its competitors with MarketBeat's FREE daily newsletter. Email Address OPK Stock News HeadlinesMarch 21, 2023 | marketwatch.comPressurized Metered-dose Inhaler Market Size and Forecast till 2028March 20, 2023 | marketwatch.comOncology Precision Medicine Market Outlook and Forecast till 2028March 21, 2023 | Health Sector Insight (Ad)Penny Stock Shows Big PotentialThe $4.37 trillion wellness market and the little-known penny stock to get on radar now. March 17, 2023 | finance.yahoo.comThe Chairman & CEO of OPKO Health, Inc. (NASDAQ:OPK), Phillip Frost, Just Bought A Few More SharesMarch 16, 2023 | americanbankingnews.comOPKO Health (NASDAQ:OPK) Coverage Initiated by Analysts at StockNews.comMarch 15, 2023 | marketwatch.comSmart Inhalers Market Outlook and Forecast till 2028March 14, 2023 | marketwatch.comClinical Laboratory Test Market Growth, Trends, and Forecasts (2023 - 2028)March 14, 2023 | americanbankingnews.comHC Wainwright Research Analysts Increase Earnings Estimates for OPKO Health, Inc. (NASDAQ:OPK)March 21, 2023 | Health Sector Insight (Ad)Penny Stock Shows Big PotentialThe $4.37 trillion wellness market and the little-known penny stock to get on radar now. March 13, 2023 | marketwatch.comFrom 2023 to 2029, Small Interfering RNA (siRNA) Therapeutics Market Size and Share | Industry GrowthMarch 11, 2023 | americanbankingnews.comOPKO Health (NASDAQ:OPK) Sees Strong Trading Volume After Insider Buying ActivityMarch 10, 2023 | marketwatch.comSmart Medication Inhalers Market Application, Product, Sales and Forecast 2023-2028March 10, 2023 | cnn.comStocks close mixed after Powell's testimony and fresh jobs dataMarch 9, 2023 | finance.yahoo.comOPKO Health to Hold Virtual R&D Day on March 20, 2023March 9, 2023 | msn.comOpko Health soars after deal with Merck for experimental Epstein-Barr vaccineMarch 8, 2023 | marketwatch.comOPKO Health Shares Jump on Licensing Deal With MerckMarch 8, 2023 | bizjournals.comOpko Health partners with pharma giant Merck to develop Epstein-Barr vaccineMarch 8, 2023 | msn.comOpko Health Surges as Merck Considers DealMarch 8, 2023 | finance.yahoo.comOPKO Health’s ModeX Therapeutics Enters into Exclusive Worldwide License and Collaboration Agreement with Merck to Develop Epstein-Barr Virus Vaccine CandidateMarch 8, 2023 | finance.yahoo.comMerck, Opko Health sign deal for experimental Epstein-Barr virus vaccineMarch 7, 2023 | marketwatch.comThe Future of Clinical Reference Laboratory Services Market 2023: Industry Trends and Forecasts by 2028March 3, 2023 | marketwatch.comPressurized Metered Dose Inhaler Market Size, Analysis, Key Segments, Share, Growth, and Forecast 2028February 28, 2023 | marketwatch.comAerosol Therapy Market Updated Report by Competitor Strategics till 2029February 26, 2023 | finance.yahoo.comOPKO Health Full Year 2022 Earnings: Revenues Beat Expectations, EPS LagsFebruary 26, 2023 | finance.yahoo.comOPKO Health, Inc. (NASDAQ:OPK) Q4 2022 Earnings Call TranscriptFebruary 25, 2023 | marketwatch.comDigital Dose Inhaler Market Size, Share, Growth Statistics, Leading Players and Forecast 2028February 24, 2023 | finance.yahoo.comOPKO Health (OPK) Q4 Earnings Match Estimates, Revenues TopSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive OPK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OPKO Health and its competitors with MarketBeat's FREE daily newsletter. Email Address OPK Company Calendar Last Earnings2/23/2023Today3/21/2023Next Earnings (Estimated)5/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:OPK CUSIP68375N10 CIK944809 Webwww.opko.com Phone(305) 575-4100Fax305-575-6015Employees4,196Year FoundedN/APrice Target and Rating Average Stock Price Forecast$3.50 High Stock Price Forecast$4.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+159.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-328,400,000.00 Net Margins-32.70% Pretax Margin-38.99% Return on Equity-15.77% Return on Assets-11.35% Debt Debt-to-Equity Ratio0.13 Current Ratio1.85 Quick Ratio1.50 Sales & Book Value Annual Sales$1.00 billion Price / Sales1.04 Cash FlowN/A Price / Cash FlowN/A Book Value$2.02 per share Price / Book0.67Miscellaneous Outstanding Shares772,650,000Free Float456,096,000Market Cap$1.04 billion OptionableOptionable Beta1.64 Key ExecutivesPhillip FrostChairman & Chief Executive OfficerElias A. ZerhouniVice Chairman & PresidentAdam E. LogalCFO, Treasurer, Chief Accounting Officer & SVPJane H. HsaioVice Chairman & Chief Technical OfficerSteven D. RubinDirector & Executive Vice President-AdministrationKey CompetitorsMannKindNASDAQ:MNKDGeronNASDAQ:GERNImmunoGenNASDAQ:IMGNLigand PharmaceuticalsNASDAQ:LGNDDynavax TechnologiesNASDAQ:DVAXView All CompetitorsInsiders & InstitutionsPhillip Md Et Al FrostBought 1,000,000 shares on 3/8/2023Total: $1.18 M ($1.18/share)Voya Investment Management LLCBought 23,537 shares on 2/28/2023Ownership: 0.213%Alliancebernstein L.P.Bought 13,469 shares on 2/16/2023Ownership: 0.080%State of WyomingBought 15,938 shares on 2/16/2023Ownership: 0.010%State of Wisconsin Investment BoardSold 19,943 shares on 2/15/2023Ownership: 0.056%View All Insider TransactionsView All Institutional Transactions OPK Stock - Frequently Asked Questions Should I buy or sell OPKO Health stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OPKO Health in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OPK shares. View OPK analyst ratings or view top-rated stocks. What is OPKO Health's stock price forecast for 2023? 2 Wall Street research analysts have issued 12 month target prices for OPKO Health's stock. Their OPK share price forecasts range from $3.00 to $4.00. On average, they anticipate the company's stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 159.3% from the stock's current price. View analysts price targets for OPK or view top-rated stocks among Wall Street analysts. How have OPK shares performed in 2023? OPKO Health's stock was trading at $1.25 on January 1st, 2023. Since then, OPK stock has increased by 8.0% and is now trading at $1.35. View the best growth stocks for 2023 here. When is OPKO Health's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023. View our OPK earnings forecast. How were OPKO Health's earnings last quarter? OPKO Health, Inc. (NASDAQ:OPK) released its quarterly earnings results on Thursday, February, 23rd. The biotechnology company reported ($0.11) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.11). The biotechnology company had revenue of $185.40 million for the quarter, compared to the consensus estimate of $168.21 million. OPKO Health had a negative trailing twelve-month return on equity of 15.77% and a negative net margin of 32.70%. The firm's revenue was down 53.8% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.11) EPS. What ETFs hold OPKO Health's stock? ETFs with the largest weight of OPKO Health (NASDAQ:OPK) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM), ALPS Medical Breakthroughs ETF (SBIO), Invesco Nasdaq Future Gen 200 ETF (QQQS), VanEck Israel ETF (ISRA), iShares U.S. Healthcare Providers ETF (IHF) and iShares Biotechnology ETF (IBB). What is Philip Frost's approval rating as OPKO Health's CEO? 21 employees have rated OPKO Health Chief Executive Officer Philip Frost on Glassdoor.com. Philip Frost has an approval rating of 16% among the company's employees. This puts Philip Frost in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of OPKO Health own? Based on aggregate information from My MarketBeat watchlists, some companies that other OPKO Health investors own include TherapeuticsMD (TXMD), Micron Technology (MU), NVIDIA (NVDA), bluebird bio (BLUE), Gilead Sciences (GILD), Pfizer (PFE), Inovio Pharmaceuticals (INO), Novavax (NVAX), Advanced Micro Devices (AMD) and AT&T (T). What is OPKO Health's stock symbol? OPKO Health trades on the NASDAQ under the ticker symbol "OPK." Who are OPKO Health's major shareholders? OPKO Health's stock is owned by a number of retail and institutional investors. Top institutional investors include Dimensional Fund Advisors LP (1.16%), Geode Capital Management LLC (1.03%), Charles Schwab Investment Management Inc. (0.57%), Millennium Management LLC (0.48%), Norges Bank (0.42%) and Deutsche Bank AG (0.30%). Insiders that own company stock include Elias A Zerhouni, Gary J Nabel, Jon R Cohen, Opko Health, Inc, Phillip Md Et Al Frost, Robert J Shovlin and Steven D Rubin. View institutional ownership trends. How do I buy shares of OPKO Health? Shares of OPK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is OPKO Health's stock price today? One share of OPK stock can currently be purchased for approximately $1.35. How much money does OPKO Health make? OPKO Health (NASDAQ:OPK) has a market capitalization of $1.04 billion and generates $1.00 billion in revenue each year. The biotechnology company earns $-328,400,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. How many employees does OPKO Health have? The company employs 4,196 workers across the globe. How can I contact OPKO Health? OPKO Health's mailing address is 4400 BISCAYNE BLVD., MIAMI FL, 33137. The official website for the company is www.opko.com. The biotechnology company can be reached via phone at (305) 575-4100, via email at mmiller@lhai.com, or via fax at 305-575-6015. This page (NASDAQ:OPK) was last updated on 3/21/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.